• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    12/5/23 4:31:06 PM ET
    $ACRS
    $ALLR
    $BCDA
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRS alert in real time by email

    Gainers

    • Phio Pharma (NASDAQ:PHIO) shares moved upwards by 19.6% to $1.34 during Tuesday's after-market session. The market value of their outstanding shares is at $3.2 million.
    • Lucy Scientific Discovery (NASDAQ:LSDI) shares moved upwards by 9.34% to $0.33. The market value of their outstanding shares is at $5.8 million.
    • Aclaris Therapeutics (NASDAQ:ACRS) stock moved upwards by 8.47% to $1.07. The company's market cap stands at $75.7 million.
    • Minerva Surgical (NASDAQ:UTRS) stock moved upwards by 8.36% to $2.85. The market value of their outstanding shares is at $25.3 million.
    • Pasithea Therapeutics (NASDAQ:KTTA) stock rose 6.77% to $0.32. The market value of their outstanding shares is at $6.5 million.
    • Phreesia (NYSE:PHR) stock increased by 5.76% to $15.6. The company's market cap stands at $861.2 million. The company's, Q3 earnings came out today.

    Losers

    • Allarity Therapeutics (NASDAQ:ALLR) stock fell 8.1% to $0.53 during Tuesday's after-market session. The company's market cap stands at $2.4 million.
    • InVivo Therapeutics Hldg (NASDAQ:NVIV) shares declined by 7.06% to $0.79. The company's market cap stands at $2.4 million.
    • Longeveron (NASDAQ:LGVN) shares declined by 6.2% to $2.0. The market value of their outstanding shares is at $47.4 million.
    • Surrozen (NASDAQ:SRZN) stock decreased by 6.01% to $0.5. The market value of their outstanding shares is at $15.3 million.
    • Impel Pharmaceuticals (NASDAQ:IMPL) stock decreased by 5.58% to $0.44. The market value of their outstanding shares is at $10.5 million.
    • BioCardia (NASDAQ:BCDA) shares decreased by 5.49% to $0.62. The company's market cap stands at $14.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRS
    $ALLR
    $BCDA
    $IMPL

    CompanyDatePrice TargetRatingAnalyst
    Phreesia Inc.
    $PHR
    4/1/2026Mkt Outperform → Mkt Perform
    Citizens
    Phreesia Inc.
    $PHR
    3/31/2026$10.00Outperform → Neutral
    Robert W. Baird
    Phreesia Inc.
    $PHR
    3/31/2026$11.00Buy → Hold
    Truist
    Phreesia Inc.
    $PHR
    3/31/2026$10.00Buy → Neutral
    Citigroup
    Phreesia Inc.
    $PHR
    3/31/2026$16.00Overweight → Neutral
    Analyst
    Phreesia Inc.
    $PHR
    3/31/2026$35.00 → $14.00Buy
    Needham
    Surrozen Inc.
    $SRZN
    2/19/2026$40.00Overweight
    Cantor Fitzgerald
    Phreesia Inc.
    $PHR
    1/9/2026$30.00Overweight
    Wells Fargo
    More analyst ratings

    $ACRS
    $ALLR
    $BCDA
    $IMPL
    SEC Filings

    View All

    Phreesia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Phreesia, Inc. (0001412408) (Filer)

    4/3/26 4:02:51 PM ET
    $PHR
    Real Estate

    BioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BioCardia, Inc. (0000925741) (Filer)

    4/2/26 9:00:11 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Surrozen Inc.

    DEFA14A - Surrozen, Inc./DE (0001824893) (Filer)

    4/1/26 4:25:56 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRS
    $ALLR
    $BCDA
    $IMPL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Tcg Crossover Gp Ii, Llc bought $1,220,362 worth of shares (48,997 units at $24.91) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    3/16/26 7:05:51 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Tcg Crossover Gp Ii, Llc bought $444,844 worth of shares (18,856 units at $23.59) (SEC Form 4)

    4 - Surrozen, Inc./DE (0001824893) (Issuer)

    2/13/26 4:19:53 PM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 2% to 273,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    2/4/26 5:47:41 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRS
    $ALLR
    $BCDA
    $IMPL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure

    SUNNYVALE, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported submission to United States Food and Drug Administration (FDA) of the CardiAMP HF clinical study data and on its plans to meet with the FDA to discuss the accelerated approval pathway for the CardiAMP® System for ischemic chronic heart failure with reduced ejection fraction (HFrEF). This meeting request is in line with previous guidance and BioCardia expects to have the meeting during this quarter. The meeting will be held under BioCardia's FDA Breakthrough Designation for

    4/2/26 10:11:34 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

    MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PAS-004 for the treatment of NF1-associated PN causing significant morbidity. "We appreciate the FDA's decision that PAS-004 meets the criteria for Fast Track designation for this indication," said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. "The ability to have early and frequent interactions with the FDA supports our goal to expeditiously develop PAS-004

    4/1/26 7:01:00 AM ET
    $KTTA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

         Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for stenoparib, enabling accelerated development in advanced ovarian cancerDurable clinical benefit observed in ongoing stenoparib ovarian cancer study, including patients treated for nearly 30 months, with new Phase 2 protocol implementedExpansion of stenoparib development beyond ovarian cancer with the launch of a VA-funded Phase 2 combination study in recurrent small cell lung cancer TARPON SPRINGS, Fla., March 31, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2

    3/31/26 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ALLR
    $BCDA
    $IMPL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Lehr Paul T

    4 - Longeveron Inc. (0001721484) (Issuer)

    4/3/26 5:00:18 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Locklear Lisa

    4 - Longeveron Inc. (0001721484) (Issuer)

    4/3/26 5:00:15 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Blass Devin

    4 - Longeveron Inc. (0001721484) (Issuer)

    4/3/26 5:00:12 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ALLR
    $BCDA
    $IMPL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Phreesia downgraded by Citizens

    Citizens downgraded Phreesia from Mkt Outperform to Mkt Perform

    4/1/26 8:19:23 AM ET
    $PHR
    Real Estate

    Phreesia downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Phreesia from Outperform to Neutral and set a new price target of $10.00

    3/31/26 8:08:36 AM ET
    $PHR
    Real Estate

    Phreesia downgraded by Truist with a new price target

    Truist downgraded Phreesia from Buy to Hold and set a new price target of $11.00

    3/31/26 8:07:55 AM ET
    $PHR
    Real Estate

    $ACRS
    $ALLR
    $BCDA
    $IMPL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ALLR
    $BCDA
    $IMPL
    Leadership Updates

    Live Leadership Updates

    View All

    Phreesia and Sesame Workshop Win Point of Care Excellence Award for Best Unbranded Campaign

    Phreesia, a leader in patient intake, outreach and activation, and Sesame Workshop, the global nonprofit behind Sesame Street, received the Point of Care Excellence Award for their pediatric health and wellness campaign. The award, announced at the Point of Care Marketing Association's (POCMA) POC Now Summit on March 18, recognizes outstanding campaigns, strategies, and individuals advancing patient and HCP engagement through innovative point-of-care (POC) marketing. The two organizations announced a five-year collaboration in August 2025, and in October launched a six-part campaign to engage millions of parents and caregivers with educational and entertaining messages to help keep thei

    3/19/26 9:03:00 PM ET
    $PHR
    Real Estate

    Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

    - Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug (ATI-045) in patients with moderate-to-severe atopic dermatitis (AD). Top line results are expected in the fourth quarter of 2026. "The strong interest in participating in this Phase 2 trial reflects the urgent need for innovative solutions in atopic dermatitis and the excitement surrou

    3/18/26 6:55:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® Appoints Stephen H. Willard as Chief Executive Officer

    Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborationsCorporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the leadership transition and continue his work in the Company's on-going business development activities MIAMI, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerati

    2/13/26 4:30:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ALLR
    $BCDA
    $IMPL
    Financials

    Live finance-specific insights

    View All

    Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

         Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for stenoparib, enabling accelerated development in advanced ovarian cancerDurable clinical benefit observed in ongoing stenoparib ovarian cancer study, including patients treated for nearly 30 months, with new Phase 2 protocol implementedExpansion of stenoparib development beyond ovarian cancer with the launch of a VA-funded Phase 2 combination study in recurrent small cell lung cancer TARPON SPRINGS, Fla., March 31, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2

    3/31/26 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phreesia Announces Fourth Quarter Fiscal 2026 Results

    Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal fourth quarter and fiscal year ended January 31, 2026. "We achieved several critical financial milestones ahead of our internal targets, including achieving positive GAAP net income ($2.3 million) and crossing $100 million of Adjusted EBITDA1 and $50 million of free cash flow2 ($78.8 million net cash from operating activities) for fiscal year 2026," said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q4 Fiscal 2026 Stakeholder Letter. Fiscal Fourth Quarter Ended January 31, 2026 Highlights Total reven

    3/30/26 4:03:00 PM ET
    $PHR
    Real Estate

    BioCardia Reports 2025 Business Highlights and Financial Results

    SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2025 and filed its annual report on Form 10-K with the Securities and Exchange Commission. The Company will host a corporate update conference call today, on Tuesday, March 24, 2026, at 4:30 PM ET, in which it will discuss business highlights. Call details and dial-in are provided below. Recent Business Highlights CardiAMP® autologous cell therapy in ischemic heart failure of reduced ejection fraction (BCDA-01) In parallel

    3/24/26 4:05:00 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRS
    $ALLR
    $BCDA
    $IMPL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/25/24 11:02:19 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/22/24 4:00:23 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/21/24 4:51:50 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care